3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Pancreatic Neoplasms
21
Triple Negative Breast Neoplasms
9
Lung Neoplasms
8
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Biliary Tract Neoplasms
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rhabdomyosarcoma
1
Resectable Pancreatic Cancer
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Neoplasms, Basal Cell
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Metastatic Adenocarcinoma of the Pancreas
1
Interventions
Temozolomide
40
Magnetic Resonance Spectroscopy
19
Radiotherapy
18
Specimen Handling
14
Radiation
12
Bevacizumab
11
Lomustine
9
pembrolizumab
6
fludarabine
5
Surgical Procedures, Operative
5
atezolizumab
4
Nivolumab
4
Ipilimumab
4
Cyclophosphamide
4
Carboplatin
4
Biopsy
4
cemiplimab
3
azeliragon
3
Immunoglobulin G
3
Disulfides
3
Aminolevulinic Acid
3
veliparib
2
trametinib
2
rocakinogene sifuplasmid
2
poly ICLC
2
olaparib
2
lutetium Lu 177 dotatate
2
durvalumab
2
dabrafenib
2
contrast agent BR1
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Albumin-Bound Paclitaxel
×
90 days
×
Clear all
NCT04528680
2026-04-13
SC9/ABX
Northwestern University
Phase 1/2
Active not recruiting
57 enrolled